On July 14, 2023, Surrozen, Inc. and Wen-Chen Yeh, M.D., Ph.D., Chief Scientific Officer, agreed that in connection with planned restructuring and reduction-in-force, Dr. Yeh will cease serving as Chief Scientific Officer and join Scientific Advisory Board effective as of July 31, 2023. On July 18, 2023, and Dr. Yeh entered into a separation agreement, or the Separation Agreement, pursuant to which Dr. Yeh will receive the following separation payments and benefits: (i) nine months of salary continuation payments of approximately $337,365.00 (which is based on his base salary in effect as of July 31, 2023), less all applicable taxes and withholdings; and (ii) payment, on Dr. Yeh?s behalf, of the premiums for group health and/or dental insurance coverage under COBRA until April 30, 2024, or the date on which Dr. Yeh becomes eligible to receive group health insurance coverage through another employer, or is otherwise ineligible for COBRA. The Separation Agreement contains a release of claims, subject to customary exceptions, and mutual covenants not to disparage.

Dr. Yeh?s equity awards will continue to vest according to their terms; provided Dr. Yeh continues to serve on Scientific Advisory Board. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, a copy of which is filed as Exhibit 10.1 hereto.